



Tatiana Iv. +22 point increase

WINTER SALE TAKE AN

Extra 30% Off

SALE STYLES WITH CODE: EXTRA

SHOP NOW

Ameritrade Get our best-in-class trading platforms

yahoo/finance Try it free

S&P 500 4,778.75 -14.33 (-0.30%)



Dow 30 36,398.08 -90.55 (-0.25%)



Nasdaq 15,741.56 -24.65 (-0.16%)



Russell 2000 2,248.79 -0.45 (-0.02%)



CISION

Beovu® (brolucizumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of neovascular (wet) age-related macular degeneration

December 17, 2021 · 7 min read

- Beovu® is an anti-VEGF that offers the option for eligible patients to start on a three-month dosing interval immediately after the loading phase with no compromise in efficacy.^{1,2}
- While wet age-related macular degeneration (AMD) represents 10 to 20 per cent of all AMD cases, it is the most severe form of AMD and is responsible for 90 per cent of vision loss associated with this disease.³

DORVAL, QC, Dec. 17, 2021 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that PrBeovu® (brolucizumab injection) is now listed on the Ontario Drug Benefit Formulary and the New Brunswick Drug Plan for the treatment of neovascular (wet) age-related macular degeneration (AMD) for eligible patients.



Novartis Logo (CNW Group/Novartis Pharmaceuticals Canada Inc.)

"We would like to thank the Governments of Ontario and New Brunswick for their leadership in making Beovu® accessible for eligible patients and remain committed to working collaboratively with the remaining provinces to ensure patients across the country can benefit from this therapy. Access to this next generation wet AMD treatment will make a difference to the vision health of Canadians and represents



Find family getaways nearby Book early

Quote Lookup

TRENDING

1. Asia May Get Lift From China Stocks Rally in U.S.: Markets Wrap
2. UPDATE 1-Putin told Biden new sanctions could rupture U.S.-Russia ties - Kremlin
3. Germany's Scholz wants G7 to be pioneer for climate-friendly growth
4. Libor Banks Subject to U.S. Conspiracy Jurisdiction, Court Says
5. Biden told Putin U.S. will respond decisively if further invasion of Ukraine - White House



Affecting more than 2.5 million Canadians, AMD is a chronic disease of the retina that causes progressive loss of central vision and is the leading cause of vision loss in people over the age of 50.^{4,5,6} There are two types of AMD – dry and wet.⁴ In wet AMD, new blood vessels grow under the macula and leak fluid into the eye causing scarring of the macula.⁷ Left untreated, wet AMD can lead to profound, rapid, and permanent loss of sight.^{4,8,9} Vision loss has a significant impact on people's quality of life and mental health – their autonomy is lost, they can't drive, read or see the faces of their loved ones, often leading them to experience feelings of social isolation and depression.^{9,10}

"Given wet AMD can be aggressive in its progression and has no cure, it can have a devastating impact on patients and their vision if patients don't adhere to the regular treatment that is required," said Dr. Peter Kertes, MD, ophthalmologist and retinal specialist, Sunnybrook Hospital, Toronto. "As someone who knows how important extended treatment intervals can be for patients, I welcome the news that Beovu® is now publicly funded in these provinces, providing a new treatment option for wet AMD."

Anti-vascular endothelial growth factor (anti-VEGF) therapy is widely regarded as the standard of care for patients with wet AMD.¹¹ Approved by Health Canada in March 2020, Beovu® is an anti-VEGF that offers the option for eligible patients to start on a three-month dosing interval immediately after the first three doses (loading phase).^{1,2}

"Regular treatment is key to preserving sight and maintaining the independence of people living with wet AMD," said Doug Earle, president and CEO, Fighting Blindness Canada. "It may be challenging to keep up with frequent appointments, especially for those living in remote or isolated communities, or requiring mobility assistance. These issues have further been exacerbated by COVID-19. The Governments of Ontario and New Brunswick's decision to add Beovu® to their provincial formularies offers the opportunity to reduce the burden of frequent injections and will be meaningful to provide treatment options for people living with wet AMD and their loved ones."

About Beovu® (brolucizumab injection)

Beovu® (brolucizumab injection) is a humanized vascular endothelial growth factor (VEGF) inhibitor that binds to VEGF-A isoforms, thereby preventing binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A binding, Beovu® suppresses endothelial cell



treatment of neovascular (wet) age-related macular degeneration (AMD) based on findings from the pivotal HAWK and HARRIER Phase III studies.¹

The full prescribing information for Beovu® can be found at: www.novartis.ca.

About Novartis in Ophthalmology

At Novartis, our mission is to discover new ways to improve and extend people's lives. In ophthalmology, we develop and deliver life-changing medicines and therapies for diseases and conditions from front to back of the eye, enabled by data and transformative technologies. Our ophthalmic solutions reach more than 150 million people per year, from premature infants to the elderly.

About Novartis Pharmaceuticals Canada Inc.

Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2020, the company invested \$45 million in research and development in Canada. Located in Dorval, Quebec, Novartis Pharmaceuticals Canada Inc. employs approximately 1,000 people in Canada and is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. The company prides itself on its commitment to diversity and to nurturing an inclusive and inspiring environment. Novartis is recognized as a Great Place to Work®, ranked among the Top 50 Best Workplaces™ in the country and is proudly named on the 2021 Best Workplaces™ for Women in Canada and Best Workplace™ for Mental Wellness lists. For further information, please consult www.novartis.ca.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

Beovu is a registered trademark.





Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Available at: [https://www.aaojournal.org/article/S0161-6420\(18\)33018-5/fulltext](https://www.aaojournal.org/article/S0161-6420(18)33018-5/fulltext). Accessed on December 2, 2021.

³ Institut national d'excellence en santé et en services sociaux. Efficacité et innocuité de la monothérapie antiangiogénique dans le traitement de la dégénérescence maculaire liée à l'âge. Available at:

https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/DMLA/Note_informative_DMLA.pdf. Accessed on December 2, 2021.

⁴ Medscape. Age-Related Macular Degeneration. Available at: https://www.medscape.com/viewarticle/848348_print. Accessed on December 2, 2021.

⁵ Fighting Blindness Canada. AMD Survey. Available at: <https://www.fightingblindness.ca/amdsurvey/>. Accessed on December 2, 2021.

⁶ Canadian Council of the Blind. The Cost of Vision Loss and Blindness in Canada. Available at: <https://www.fightingblindness.ca/wp-content/uploads/2021/05/Deloitte-Final-Acc-of-VL-and-Blindness-in-Canada-May-2021.pdf>. Accessed on December 2, 2021.

⁷ American Academy of Ophthalmology. What is Macular Degeneration? Available at: <https://www.aao.org/eye-health/diseases/amd-macular-degeneration>. Accessed on December 2, 2021.

⁸ Fighting Blindness Canada. Age Related Macular Degeneration. Available at: <https://www.fightingblindness.ca/eyehealth/eye-diseases/age-related-macular-degeneration/>. Accessed on December 2, 2021.

⁹ Wykoff CC et al. Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration. *J Manag Care Spec Pharm*. 2018 Feb. Available at: <https://pubmed.ncbi.nlm.nih.gov/29383980/>. Accessed on December 2, 2021.

¹⁰ American Macular Degeneration Foundation. Depression in Age-related Macular Degeneration. Available at: <https://www.macular.org/depression-amd-arnold-wyse-md>. Accessed on December 2, 2021.

¹¹ CADTH Therapeutic Report. Anti-Vascular Endothelial Growth Factor Drugs for the Treatment of Retinal Conditions Recommendations Report. 2016. Available at: https://www.cadth.ca/sites/default/files/pdf/TR0009_Anti-VEGFs_Recs_Report.pdf. Accessed on December 2, 2021.

SOURCE Novartis Pharmaceuticals Canada Inc.

Cision

View original content to download multimedia:

<http://www.newswire.ca/en/releases/archive/December2021/17/c0757.html>





Popular in the Community



Invest in a career where the demand is growing
Train to be a paralegal!
Enroll Now

AdChoices

Sponsored

COLE HAAN
THE WINTER SALE
TAKE AN
Extra 30% Off
SALE STYLES WITH CODE: EXTRA
SHOP NOW

RECOMMENDED STORIES



MarketWatch

Daily average of COVID-19 cases surges past 300,000, but more data emerge suggesting omicron is less dangerous

There are a lot more people sick with COVID-19 today than ever before, but evidence is piling up to suggest the surging omicron variant is less severe than the previously dominant delta variant.

6h ago



TipRanks

These 2 "Strong Buy" Penny Stocks Are Poised to Take Off, Says Raymond James

Let's talk about penny stocks. These are equities that trade for less than \$5 per share, the very bottom of the price range. While they are priced that low for a reason – and the reasons may vary – low price in itself doesn't...

1d ago



Ad • Chaikin Analytics

Wall Street legend warns "A strange day is coming"

A massive and surprising new transition could soon impact the wealth of thousands, while leaving everyone else worse off than before.



COLE HAAN
THE WINTER SALE
TAKE AN
Extra 30% Off
SALE STYLES WITH CODE: EXTRA
SHOP NOW

Yahoo Finance

Why Wall Street set new records on the same day COVID-19 cases did

Another day, another shattered record of COVID-19 infections in the United States — and yet another set of new milestones in the Dow and S&P 500, as Santa Claus continues to bestow gifts on Wall Street.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.